Literature DB >> 25070211

[Procedural aspects in primary PCI: arterial access, stent selection, thrombectomy and treatment of non-culprit lesions].

N F Boeder1, C W Hamm, H M Nef.   

Abstract

Acute myocardial infarction was one of the most common causes of death in Germany in 2011. According to the guidelines of the European Society for Cardiology, systemic fibrinolysis and primary percutaneous coronary intervention (PCI) are the methods of choice for acute treatment. Primary PCI should be given priority due to its superiority. The transradial access should be preferred due to the lower bleeding complication rate. In the selection of stents the new generation of drug-eluting stents (DES) are superior to the first generation of bare metal stents (BMS). It has now been demonstrated that the incident rates of DES (e.g. mortality, target vessel revascularization, early and late stent thrombosis and myocardial infarction) are significantly lower. For bioresorbable scaffolds (BRS) long-term results for the use in treatment of ST-elevation myocardial infarction (STEMI) are not yet available but initial results are very promising. However, the selection of a stent needs to be done on an individual basis in order to do justice to all aspects. Data with respect to thrombectomy in acute treatment are heterogeneous. Currently, a thorough consideration of all aspects is necessary because thrombus aspiration can also be associated with an increased rate of incidents. In a state of hemodynamic stability only so-called culprit lesions should currently be treated with a stent. Elective interventions on further stenoses should be carried out after consideration of individual factors and if necessary evaluation of the hemodynamic relevance.

Entities:  

Mesh:

Year:  2014        PMID: 25070211     DOI: 10.1007/s00059-014-4133-y

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  47 in total

1.  Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study.

Authors:  Peter Wenaweser; Joost Daemen; Marcel Zwahlen; Ron van Domburg; Peter Jüni; Sophia Vaina; Gerrit Hellige; Keiichi Tsuchida; Cyrill Morger; Eric Boersma; Neville Kukreja; Bernhard Meier; Patrick W Serruys; Stephan Windecker
Journal:  J Am Coll Cardiol       Date:  2008-09-30       Impact factor: 24.094

2.  Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS)--study design.

Authors:  Tone Svilaas; Iwan C C van der Horst; Felix Zijlstra
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

3.  Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study.

Authors:  Roberto Diletti; Antonios Karanasos; Takashi Muramatsu; Shimpei Nakatani; Nicolas M Van Mieghem; Yoshinobu Onuma; Sjoerd T Nauta; Yuki Ishibashi; Mattie J Lenzen; Jurgen Ligthart; Carl Schultz; Evelyn Regar; Peter P de Jaegere; Patrick W Serruys; Felix Zijlstra; Robert Jan van Geuns
Journal:  Eur Heart J       Date:  2014-01-06       Impact factor: 29.983

4.  In-hospital and long-term outcomes of multivessel percutaneous coronary revascularization after acute myocardial infarction.

Authors:  Lin Y Chen; Ryan J Lennon; J Aaron Grantham; Peter B Berger; Verghese Mathew; Mandeep Singh; David R Holmes; Charanjit S Rihal
Journal:  Am J Cardiol       Date:  2005-02-01       Impact factor: 2.778

5.  Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.

Authors:  Sanjit S Jolly; Salim Yusuf; John Cairns; Kari Niemelä; Denis Xavier; Petr Widimsky; Andrzej Budaj; Matti Niemelä; Vicent Valentin; Basil S Lewis; Alvaro Avezum; Philippe Gabriel Steg; Sunil V Rao; Peggy Gao; Rizwan Afzal; Campbell D Joyner; Susan Chrolavicius; Shamir R Mehta
Journal:  Lancet       Date:  2011-04-04       Impact factor: 79.321

6.  Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction.

Authors:  Tomas Jernberg; Per Johanson; Claes Held; Bodil Svennblad; Johan Lindbäck; Lars Wallentin
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

7.  Checking consistency in mixed treatment comparison meta-analysis.

Authors:  S Dias; N J Welton; D M Caldwell; A E Ades
Journal:  Stat Med       Date:  2010-03-30       Impact factor: 2.373

8.  Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial.

Authors:  Martial Hamon; Lars H Rasmussen; Steven V Manoukian; Angel Cequier; Michael A Lincoff; Hans-Jürgen Rupprecht; Bernard J Gersh; Tift Mann; Michel E Bertrand; Roxana Mehran; Gregg W Stone
Journal:  EuroIntervention       Date:  2009-05       Impact factor: 6.534

9.  Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2.

Authors:  P Widimský; T Budesínský; D Vorác; L Groch; M Zelízko; M Aschermann; M Branny; J St'ásek; P Formánek
Journal:  Eur Heart J       Date:  2003-01       Impact factor: 29.983

10.  Thrombus aspiration complicated by systemic embolization in patients with acute myocardial infarction.

Authors:  Ming-Shyan Lin; Lung-Sheng Wu; Nai-Jen Cheng; Pi-Chi Lin; Chi-Jen Chang
Journal:  Circ J       Date:  2008-12-27       Impact factor: 2.993

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.